SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Sun Yat-sen — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSun Yat-sen
Date of birth1866-11-12
IdentifiersMRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183
Document date1924-09-21
AuthorWen-Li Huang, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Mr. Sun is a 57-year-old physician by training and political leader who comes for his yearly preventive visit, timed with the day-8 infusion of cycle 6, which he had this morning. The cold of three weeks ago cleared within a week without fever. He has been working most days and has kept his weight steady with the dietitian's advice. He meets the palliative care team every three to four weeks and has talked with them about what matters most to him. He asked which preventive services still make sense for him now, and wants the vaccines that protect him during treatment. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 57
Cancer treatmentCycle 6 of gemcitabine, cisplatin and durvalumab; day-8 dose today
Recent illnessCold cleared within a week
WeightSteady at about 59 kg
His questionWhich preventive services still make sense now

Health risk assessment. Completed by the patient on the clinic tablet before the visit and reviewed with him by Dr. Huang. [S]

DomainFinding
Self-rated healthFair; tired in the afternoons, but working most days
PsychosocialSupported by colleagues and his household; talks openly with the palliative care team
Substance useAlcohol rarely, at formal dinners; none since starting treatment; no drugs
TobaccoNever smoked
Physical activityWalks 30 minutes most days
NutritionSmall frequent meals and a protein drink each day, as the dietitian advised
SleepSix to seven hours; occasional night waking
Infection precautionsHand hygiene; avoids crowds in the week after day-8 doses; has a thermometer
Safety at homeFeels safe; smoke alarm working; no firearm at home
Road safetyWears a seat belt; is driven to most meetings
Activities of daily livingIndependent

Review of Systems

SystemResultFinding
ConstitutionalPositiveAfternoon tiredness; no fever; weight steady
EyesNegativeReading glasses; no change
Ears, nose, mouth, and throatNegativeCold resolved; no ringing in the ears or hearing change; no mouth sores
CardiovascularNegativeNo chest pain or leg swelling
RespiratoryNegativeCough gone; no breathlessness
GastrointestinalNegativeMild nausea on the two days after each infusion, eased by ondansetron; no jaundice; ache under the right ribs 1 of 10
GenitourinaryNegativeNo urinary symptoms
MusculoskeletalNegativeNo joint pain
IntegumentaryNegativeNo rash or itching
NeurologicalNegativeNo numbness or tingling
EndocrineNegativeNo heat or cold intolerance, thirst, or excess urination
PsychiatricNegativeMood steady; PHQ-2 score 1

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a dayTwo tablets by mouth every 8 hours as needed, no more than 3,000 mg a dayOral route1924-05-04activeS
Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cyclesIntravenous route1924-06-01activeS
Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cycles, with hydrationIntravenous route1924-06-01activeS
Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycleDay 1 of each 21-day cycle with chemotherapy, then every 4 weeks aloneIntravenous route1924-06-01activeS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet by mouth every 8 hours as needed for nauseaOral route1924-06-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1924-09-21Body height165cmS
1924-09-21Body weight59.4kgS
1924-09-21Body mass index (BMI) [Ratio]21.8kg/m2S
1924-09-21Systolic blood pressure122mm[Hg]S
1924-09-21Diastolic blood pressure76mm[Hg]S
1924-09-21Heart rate80/minS
1924-09-21Respiratory rate16/minS
1924-09-21Body temperature36.6CelS
1924-09-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1924-09-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 1924-09-21; see the Vital Signs section. [S]

SystemFinding
ConstitutionalThin but well; weight 59.4 kg, BMI 21.8; blood pressure 122/76, pulse 80
Ears, nose, mouth, and throatThroat normal; no thrush; whispered voice heard at arm's length in both ears
RespiratoryClear to auscultation bilaterally
AbdomenLiver edge firm, 2 cm below the right costal margin, smaller than at diagnosis; no ascites; no tenderness
SkinPort site clean; no jaundice or rash
PsychiatricComposed, engaged, precise in his questions

Problems

ProblemClinical statusVerificationCodeProvenance
Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arrangedresolvedconfirmed R19.01S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis.
Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinomaactiveconfirmed C23S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy.
Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitoredactiveconfirmed Z86.19S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis.
Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectableactiveconfirmed C78.6S — Synthetic finding anchored to the peritoneal metastases reported at autopsy.
Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolvedresolvedconfirmed J06.9S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today122/76 mmHg
Depression screeningCompleted todayPHQ-2 score 1; PHQ-9 tracked at oncology visits
Unhealthy alcohol use screeningCompleted todayDrinks rarely; none since treatment began
Tobacco useCompleted todayNever smoked
Colorectal cancer screeningNot indicatedNever screened; with metastatic gallbladder cancer the benefit of screening would not be realized, and he agreed not to pursue it now
Prostate cancer screeningNot indicatedDiscussed; not offered while he has metastatic cancer
Lung cancer screeningNot indicatedNever smoked; he has CT scans of the chest every 2 to 3 months for his cancer
Diabetes screeningNot indicatedNot overweight; glucose 98 mg/dL at intake
HIV screeningOrderedNever tested; once-in-a-lifetime test drawn today with his agreement
Hepatitis C screeningUp to dateAntibody negative at intake
Hepatitis B screeningUp to dateResolved infection at intake; HBV DNA monitored during treatment; vaccination not needed
Influenza vaccineCompleted todayInactivated vaccine given today
COVID-19 vaccineCompleted todayGiven today; immunocompromised adults may need an additional dose, to be reviewed with the oncology team
Pneumococcal vaccineCompleted todayPCV20 given today because chemotherapy suppresses his immunity; no further pneumococcal dose needed
Zoster vaccineDueRecombinant zoster vaccine recommended for immunocompromised adults; first dose at the next visit, second one to two months later
Tetanus, diphtheria, and pertussisUp to dateTdap after a hand cut five years ago

Immunizations given today: Influenza vaccine, 1924-1925 season (inactivated); COVID-19 vaccine, 1924-1925 formula; Pneumococcal conjugate vaccine (PCV20), for immunosuppression by chemotherapy [S]

Guideline basis: Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Colorectal Cancer: Screening (2021); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: HIV result by phone. Cycle 7 as booked. Oncology visit before cycle 8 with restaging CT; first zoster vaccine dose then. Next preventive visit in one year. Next scheduled visit 1924-10-26: before cycle 8: restaging CT, toxicity review, low magnesium, and the plan for maintenance durvalumab. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 25 minutes, with his consent, building on his conversations with the palliative care team. He named a health care agent, recorded in the confidential part of the chart and not named here. He wants to be told everything plainly and to make his own decisions while he can. He wants treatment that lets him keep working and thinking clearly; if his illness reached the point where he could no longer communicate and there was no prospect of recovery, he would not want to be kept alive on machines and would want comfort care. He chose to wait before completing a portable medical order form and will revisit it with the palliative care team. To be revisited when treatment changes. [S]